

December 10, 2020

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra - Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
Luxembourg Stock Exchange Bourse de Luxembourg BP 165, L-2011 Luxembourg Siege social 11, avenue de la Porte-Neuve	London Stock Exchange 10 Paternoster Square London EC4M 7LS United Kingdom

Sub: Disclosure under Regulation 23(9) of SEBI (LODR) Regulations, 2015, for the half year ended on September 30, 2020

Dear Sir/Madam



Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we hereby submit the disclosure of Related Party transactions, on a consolidated basis for the half year ended September 30, 2020.

Kindly take the above on your records.

Thanking you

Yours faithfully

For **Orchid Pharma Limited**



Manish Dhanuka
Managing Director



Orchid Pharma Limited

Notes to the financial statements for the half yearly ended September 30, 2020

(All amounts are in lakhs of Indian Rupees, unless otherwise stated)

Consolidated disclosure of Related Party Transaction & balances for the Half year ended September 30, 2020

Related party disclosure

a) Nature of Related party

Holding company Dhanuka Laboratories Limited (w.e.f. March 31, 2020)


Subsidiary Companies

Orchid Europe Limited, UK
Orchid Pharmaceuticals Inc., USA
Orgenus Pharma Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc USA.)
Orchid Pharma Inc / Karalex Pharma USA, (Subsidiary of Orchid Pharmaceuticals Inc, USA)
Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa
Bexel Pharmaceuticals Inc., USA
Diakron Pharmaceuticals Inc., USA

Key Management Personnel and their relatives

Mr. Ram Gopal Agarwal*	Chairman and Non-Executive director (w.e.f. June 29, 2020)
Mr. Manish Dhanuka*	Managing Director (w.e.f. June 29, 2020)
Mr. Mridul Dhanuka*	Whole time Director (w.e.f. June 29, 2020)
Mr. Arun Kumar Dhanuka	Non-Executive Director (w.e.f. March 31, 2020)
Mr. Sunil Gupta	Chief Financial Officer (w.e.f. June 29, 2020)
Ms. Nikita K	Company Secretary (w.e.f. March 5, 2020)

* Joined the Board as Director with effective from March 31, 2020



Manish Dhanuka



S. K. Gupta



Related Party under Section 2(76) (iii) and 2(76) (iv) of the Companies Act, 2013 Synmedic Laboratories
Otsuka Chemical (India) Private Limited

Transactions with related parties are as follows (April 01, 2020 to September 30, 2020)

Name of the Party	Nature of Relationship	Nature of Transaction	Amount in INR Lakhs
Dhanuka Laboratories Limited	Holding Company	Purchase of Goods	387.07
Otsuka Chemical (India) Private Limited	Related Party Under Sec 2(76)(iv)	Purchase of Goods	2,385.15
Orchid Pharma INC	Subsidiary Company	Sale of Goods	308.98
Synmedic Laboratories	Related Party Under Sec 2(76)(iii)	Sale of Goods	4.94
Managing Director, Whole Time Director and Company Secretary	Key Management Personnel	Compensation (short term employee benefit)	37.48
Shri Ram Gopal Agarwal and Shri Arun Kumar Dhanuka	Non- Executive Directors	Sitting Fee	0.80

Balances with related parties are as follows (As on 30th September 2020)

Name of the Party	Nature of Relationship	Nature of Transaction	Amount in INR Lakhs
Dhanuka Laboratories Limited	Holding Company	Trade Advance	66.15
Otsuka Chemical (India) Private Limited	Related Party Under Sec 2(76)(iv)	Trade Advance	15.09
Orchid Europe Limited	Subsidiary Company	Trade Payable	30.65
Orchid Pharma INC	Subsidiary Company	Trade Receivables	3072.56
Dhanuka Laboratories Limited	Holding Company	0% Optionally Convertible Debentures	14,300.00
Synmedic Laboratories	Related Party Under Sec 2(76)(iii)	Trade Receivables	4.94

For Orchid Pharma Limited

Manish Dhanuka
Managing Director



For Orchid Pharma Limited

Sunil Kumar Gupta
Chief Financial Officer